Selcen KORKMAZ, ŞENGÜL YÜKSEL, YASEMİN ERSOY

The genotoxicity of Tenofovir disoproxil fumarate in HBV-infected patients

Tenofovir disoproxil fumarate (TDF) is an acyclic nucleotide reverse transcriptase inhibitor used as antiviral therapeutic drug in hepatitis B virus (HBV) infection treatment. We investigated whether HBV itself or TDF could enhance genotoxicity in HBV infected patients. A total of 30 HBV-infected patients were included in this study: 10 were untreated, 10 took therapy for 6 months, 10 took therapy for 12 months and a further 15 were control group. We used the micronucleus test (MN) and mitotic index (MI) to assess the genotoxic effects of TDF. MN and MI frequency were significantly increased in all the HBV-infected patient groups when compared to control. However, significant differences were not found between different time points within the therapy groups. The current data indicate that chronic HBV infection without treatment has an effect on MN and MI. TDF administration at therapeutic doses for 12 months also did not reduce the MI and MN, suggesting its protective action against HBV induced genotoxic damage. Larger-scale and longtime studies are required for a better understanding of the genotoxicity of TDF.

PDF

___

Bayram S, Topaktas M. Confirmation of the chromosome damaging effects of lamivudine in In vitro human peripheral blood lymphocytes. Environmental Mol Mutagenesis. 2008;49:328-33.

Blackadar CB. Hepatocellular carcinoma and other liver diseases among Greenlanders chronically infected with hepatitis B virus: a population-based study. J Natl Cancer Inst. 2012;104:1515–6.

Brüning A, Burger P, Gingelmaier A, et al. The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells. Invest New Drugs. 2012;30:1389-95.

Buti M, Homs M. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Expert Rev Gastroenterol Hepatol. 2012;6:413-21.

de Almeida TM, Leitão RC, Andrade JD, et al. Detection of micronuclei formation and nuclear anomalies in regenerative nodules of human cirrhotic livers and relationship to hepatocellular carcinoma. Cancer Genet Cytogenet. 2004;150:16-21.

Gordon SC, Krastev Z, Horban A, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology. 2013;58:505–13.

Idilman R, Gunsar F, Koruk M, et al. Yurdaydin C. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting. J Viral Hepat. 2015; 22:504-10.

Kim HJ, Cho JY, KimYJ, et al. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Korean J Intern Med. 2015;30:32-41.

Kurtoglu EL, Yuksel S. Genotoxic effects of Tacrolimus on Human Lymphocyte Cells, Russian J Genet. 2012;48:651-5.

Leeansyah E, Cameron PU, Solomon A, Tet al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013;207:1157-65.

Livezey KW, Negorev D, Simon D. Increased chromosomal alterations and micronuclei formation in human hepatoma HepG2 cells transfected with the hepatitis B virus HBX gene. Mutat Research. 2002;505:63-74.

Lourenço ED, do Amaral VS, Lehmann M, et al. Micronuclei induced by reverse transcriptase inhibitors in mononucleated and binucleated cells as assessed by the cytokinesis-block micronucleus assay. Genetics and Molecular Biology. 2010;33:756-60.

Luzhna L, Kathiria P, Kovalchuk O. Micronuclei in genotoxicity assessment: from genetics to epigenetics and beyond. Front Genet. 2013; 4:131.

Matsuda Y, Ichida T. Impact of hepatitis B virus X protein on the DNA damage response during hepatocarcinogenesis. Clin Mol Morphol. 2009;42:138-42

Menendez-Arias L, Alvarez M, Pacheco B. Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. Curr Opin Virol. 2014;8:1-9.

Minarovits J, Demcsák A, Banati F, et al. Epigenetic Dysregulation in VirusAssociated Neoplasms. Adv Exp Med Biol. 2016;879:71-90.

Olivero OA. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Environ Mol Mutagen. 2007;48:215-23.

Ozkal P, Ilgin-Ruhi H, Akdogan M, et al. The genotoxic effects of hepatitis B virus to host DNA. Mutagenesis. 2005;20:147-50.

Poirier MC, Gibbons AT, Rugeles MT et al. Fetal consequences of maternal antiretroviral nucleoside reverse transcriptase inhibitor use in human and nonhuman primate pregnancy. Curr Opin Pediatr. 2015;27:233-9.

Revill PA, Locarnini SA. New perspectives on the hepatitis B virus life cycle in the human liver. J Clin Invest. 2016;126:833-6.

Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. The Lancet. 2015;386;1546-55.

Tarocchi M, Polvani S, Marroncini G, et al. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol. 2014;20:11630-40.

Vivanti A, Soheili TS, Cuccuini W, et al. Comparing genotoxic signatures in cord blood cells from neonates exposed in utero to zidovudine or tenofovir. AIDS. 2015;29:1319-24.

Wu Q, Beland FA, Chang CW, et al. Role of DNA Repair Pathways in Response to Zidovudine-induced DNA Damage in Immortalized Human Liver THLE2 Cells. Int J Biomed Sci. 2013;9:18-25.

Yuen MF, Ahn SH, Chen DS, et al. Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations. J Clin Gastroenterol. 2016;50:286-94.